ProQR Therapeutics (PRQR) Receivables - Net (2022 - 2025)
ProQR Therapeutics (PRQR) has disclosed Receivables - Net for 3 consecutive years, with $7.9 million as the latest value for Q4 2025.
- Quarterly Receivables - Net rose 97.69% to $7.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.9 million through Dec 2025, up 97.69% year-over-year, with the annual reading at $7.9 million for FY2025, 97.69% up from the prior year.
- Receivables - Net hit $7.9 million in Q4 2025 for ProQR Therapeutics, up from $4.0 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $57.4 million in Q4 2022 to a low of $4.0 million in Q4 2024.
- Historically, Receivables - Net has averaged $23.1 million across 3 years, with a median of $7.9 million in 2025.
- Biggest YoY gain for Receivables - Net was 97.69% in 2025; the steepest drop was 97.69% in 2025.
- Year by year, Receivables - Net stood at $57.4 million in 2022, then plummeted by 93.02% to $4.0 million in 2024, then skyrocketed by 97.69% to $7.9 million in 2025.
- Business Quant data shows Receivables - Net for PRQR at $7.9 million in Q4 2025, $4.0 million in Q4 2024, and $57.4 million in Q4 2022.